S100A2 seems to have a variable pattern of expression with some evidence pointing to higher expression in normal tissues and early or premalignant issues, but other types of cancer, such as lung cancer, have a higher expression in advanced lesions that correlate with poorer clinical prognosis. This evidence concerns the gene S100A2 and lung cancer.